<DOC>
	<DOCNO>NCT02181699</DOCNO>
	<brief_summary>This first human , non-randomized , open-label , dose escalation study investigate safety , pharmacokinetics , immunogenicity pharmacodynamics repeat dos KHK2823 .</brief_summary>
	<brief_title>Study KHK2823 Patients With Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>This Phase 1 , multi-center , open-label , dose-escalation study KHK2823 adult patient previously untreated AML candidate intensive remission induction therapy ; relapsed/refractory AML standard therapy available appropriate ; relapsed/refractory MDS receive prior therapy hypomethylating agent , decitabine azacitidine candidate receive hypomethylating agent , would include high risk transfusion-dependent low risk patient . Patients must document primary secondary AML MDS accord World Health Organization ( WHO ) criterion . Following provision sign informed consent , patient screen entry study . The study consist 2 part . In Part 1 , 3 6 patient per cohort enrol sequentially 7 dose-escalation cohort establish MTD . KHK2823 administer weekly . In Part 2 , additional 18 patient may enrol evaluate safety , PK , PD , potential anti-leukemic activity KHK2823 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Males female ≥ 18 year old previously untreated AML candidate intensive remission induction therapy ; relapsed/refractory AML standard therapy available appropriate ; relapsed/refractory MDS receive prior therapy hypomethylating agent candidate receive hypomethylating agent Histopathologically/cytologically document primary secondary AML , define WHO criterion , MDS , confirm pathology review treat institution Eastern Cooperative Oncology Group ( ECOG ) performance status score 02 Life expectancy least 3 month Histological diagnosis acute promyelocytic leukemia ( FAB Type M3 ) Clinically significant central nervous system leukemia Treatment underlie hematologic condition systemic therapy treatment period , include chemotherapy , radiation investigational therapy , within 2 week prior KHK2823 administration ; immunotherapy within 30 day prior KHK2823 administration ; exception hydroxyurea ( Hydrea® ) treatment hyperleukocytosis , must discontinue least 24 hour prior first dose KHK2823</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>